Alpha1Health.com | Therapy for Alpha-1 Antitrypsin Deficiency | How ARALAST Works

How ARALAST Works

ARALAST [Alpha1-Proteinase Inhibitor (Human)] is an augmentation therapy which works by increasing the levels of alpha1-antitrypsin (AAT) in your blood and lungs.

If you have AAT deficiency, your body does not produce enough A1-PI. Having the right amount of A1-PI, also called alpha1-antitrypsin (AAT), is important to protect your lungs from damage caused by neutrophil elastase (NE), an enzyme released by white blood cells. To learn more about the important role AAT plays in protecting your lungs, visit the Alpha-1 Reading Room.

ARALAST is administered by intravenous infusion once a week. With augmentation therapy, blood levels of A1-PI rise to levels exceeding the "protective threshold," as recommended by the American Thoracic Society and European Respiratory Society.1

It is important to understand that ARALAST augmentation therapy is not a cure for AAT deficiency. It cannot repair damage that has already occurred in your lungs. However, augmentation therapy with ARALAST may slow further progression of lung disease.

ARALAST [Alpha1-Proteinase Inhibitor (Human)] is indicated for chronic augmentation therapy in patients having congenital deficiency of A1-PI with clinically evident emphysema. ARALAST is not indicated as therapy for lung disease patients in whom congenital A1-PI deficiency has not been established.

Please review the Important Safety Information and the Full Prescribing Information

  1. Stoller JK, Rouhani F, Brantly M, et al. Biochemical efficacy and safety of a new pooled human plasma alpha (1)-antitrypsin, Respitin. Chest. 2002; 122:66-74.]
adobe reader To view PDF, you will need Adobe® Acrobat® Reader® software.